Fennec Pharmaceuticals Inc FENC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 07/23/21 EDT
6.58quote price arrow down-0.13 (-1.94%)
Volume
65,006
52 week range
4.80 - 10.67

...

Loading . . .
  • Open6.97
  • Day High6.97
  • Day Low6.46
  • Prev Close6.71
  • 52 Week High10.67
  • 52 Week High Date08/10/20
  • 52 Week Low4.80
  • 52 Week Low Date09/04/20

Key Stats

  • Market Cap171.08M
  • Shares Out26.00M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.07
  • YTD % Change-11.68

KEY STATS

  • Open6.97
  • Day High6.97
  • Day Low6.46
  • Prev Close6.71
  • 52 Week High10.67
  • 52 Week High Date08/10/20
  • 52 Week Low4.80
  • 52 Week Low Date09/04/20
  • Market Cap171.08M
  • Shares Out26.00M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.07
  • YTD % Change-11.68

RATIOS/PROFITABILITY

  • EPS (TTM)-0.76
  • P/E (TTM)-8.70
  • Fwd P/E (NTM)286.09
  • EBITDA (MRQ)-18.973M
  • ROE (MRQ)-113.89%
  • Revenue (MRQ)170,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-11,185.88%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Fennec Pharmaceuticals Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of...
Khalid Islam Ph.D.
Non-Executive Chairman
Rostislav Raykov
Chief Executive Officer
Robert Andrade
Chief Financial Officer
Address
68 Tw Alexander Dr
PO Box 13628
Durham, NC
27709-3628
United States